A Case Report on Etoricoxib Induced Stevens Johnson Syndrome
1, 1
- 1Department of Pharmacy Practice, Malla Reddy Pharmacy College, Maisammaguda, Secunderabad, Telangana, INDIA.
CORRESPONDENCE
Poludasari Shravan Kumar
Department of Pharmacy Practice, Malla Reddy Pharmacy College, Maisammaguda, Secunderabad, Telangana, INDIA.
Volume 14, Issue 1 · pp. 65-67 · 2021 · DOI: 10.5530/ijopp.14.1.13
ABSTRACT
Etoricoxib is a selective cyclo-oxygenase enzyme-2 (COX-2) inhibitor which is majorly indicated in the treatment of inflammatory disorders such as rheumatoid arthritis, osteoarthritis and gout. Etoricoxib selectively inhibits COX-2 thereby inhibiting the conversion of arachidonic acid to prostaglandins (PG’s). Stevens–Johnson Syndrome (SJS) is a rare, life threatening hypersensitivity reaction that predominantly affects skin and mucous membrane which is characterised by extensive epidermal necrosis. Some of the medications which are associated with the development of Stevens Johnson syndrome include xanthine oxidase inhibitors such as allopurinol, antiepileptic medications such as carbamazepine, lamotrigine, phenytoin and Non-Steroidal Anti-Inflammatory Drugs (NSAID’s). In this case report, we summarize regarding a patient who developed SJS after usage of etoricoxib that was managed by cessation of the offending agent and symptomatic treatment concomitant with supportive care.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kumar, P. S., & Tharuni, B. (2021). A Case Report on Etoricoxib Induced Stevens Johnson Syndrome. Indian Journal of Pharmacy Practice, 14(1), 65-67. https://doi.org/10.5530/ijopp.14.1.13
Copyright and licence
© 2021 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0